VEGF reflects on itself

North American researchers have chemically synthesized a d-protein ligand that blocked the binding of VEGF to its receptor in vitro.¹

Reflexion Pharmaceuticals Inc. has licensed the compound and thinks it could have better stability and bioavailability than anti-VEGF antibodies that are l-isomer proteins. The company is optimizing its molecule before doing head-to-head comparisons with Lucentis and Avastin in animal models of age-related macular degeneration...